Antitumor activity
NSCLC, tumor, SD, PDAC
DISEASE, NSCLC, BEST, TUMOR
No ORs were seen in the dose-escalation cohorts; the best percentage changes in target lesion size from baseline are shown in Supplementary Figure 3, including 1 patient in the oleclumab 40 mg/kg combination therapy group who had a > 30% decrease in target lesion size.Stable disease (SD) ≥ 8 weeks was observed in 14.3% of patients in the monotherapy dose-escalation cohorts and in 8.3% of patients in the combination therapy dose-escalation cohorts. Median PFS was 1.8 months in both the monotherapy and combination therapy dose-escalation cohorts, with respective 6-month PFS rates of 3.3 and 4.5%. Median OS was 6.1 months in the monotherapy cohort and 5.6 months in the combination therapy cohort, with 9-month OS rates of 42.8 and 35.6%, respectively.In the MSS-CRC expansion cohort, 1 patient (2.4%), a 38-year-old female who was a previous smoker and had received 4 prior chemotherapy regimens, had a CR following an initial partial response (PR), with a DoR of 36.2 months (Fig. Best percentage change from baseline in target lesions in the In the PDAC expansion cohort, 2 patients (4.8%) had ORs, including 1 CR in a 58-year-old female who had had a PR to her one prior systemic chemotherapy regimen, and 1 PR in a 67-year-old female with confirmed MSS PDAC who had had a PR to her one prior chemotherapy regimen; both responses were ongoing at database lock, with DoRs of 30.4 and 37.0 months, respectively (Fig. In the EGFRm NSCLC expansion cohort, 4 patients (9.5%) had PRs, with a median DoR of 14.8 months (range, 5.6–24.0; 1 response ongoing) (Fig. Baseline tumor CD73 expression and association with clinical response is summarized in Fig. In all 3 expansion cohorts, the median PFS was 1.8 months; 6-month PFS rates in the MSS-CRC, PDAC, and NSCLC cohorts were 5.4%, 13.2%, and 16.0%, respectively. Median OS was 7.0 months in the MSS-CRC cohort, 6.3 months in the PDAC cohort, and 11.3 months in the NSCLC cohort, with 9-month OS rates of 31.2%, 31.6%, and 57.0%, respectively.